Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management
Exagen Inc. (XGN)
Last exagen inc. earnings: 3/25 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN DIEGO, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world’s leading healthcare companies, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus. At the center of the program are the proprietary AVISE laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential. This extension follows a similar one-year extension that Exagen and GSK entered into last year, and will continue to support the shared goal of helping SLE patients shorten the time to their diagnos
Show less
Read more
Impact Snapshot
Event Time:
XGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XGN alerts
High impacting Exagen Inc. news events
Weekly update
A roundup of the hottest topics
XGN
News
- Exagen Inc. (NASDAQ: XGN) had its price target raised by analysts at Cantor Fitzgerald from $5.00 to $7.00. They now have an "overweight" rating on the stock.MarketBeat
- Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full YearGlobeNewswire
- Exagen Announces Campaign for Lupus Awareness Month [Yahoo! Finance]Yahoo! Finance
- Exagen Announces Campaign for Lupus Awareness MonthGlobeNewswire
- Lupus Foundation of America Drives Nationwide Effort to Make Lupus Visible During Lupus Awareness Month [Yahoo! Finance]Yahoo! Finance
XGN
Earnings
- 5/13/24 - Beat
XGN
Analyst Actions
- 5/14/24 - Cantor Fitzgerald
XGN
Sec Filings
- 5/16/24 - Form 4
- 5/13/24 - Form S-8
- 5/13/24 - Form 10-Q
- XGN's page on the SEC website